These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 620410)
1. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410 [TBL] [Abstract][Full Text] [Related]
2. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites. Jardine I; Brundrett R; Colvin M; Fenselau C Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214 [TBL] [Abstract][Full Text] [Related]
3. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406 [TBL] [Abstract][Full Text] [Related]
4. Alkylating properties of phosphoramide mustard. Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171 [TBL] [Abstract][Full Text] [Related]
5. Review of the metabolism and mode of action of cyclophosphamide. Fenselau C J Assoc Off Anal Chem; 1976 Sep; 59(5):1028-36. PubMed ID: 965325 [TBL] [Abstract][Full Text] [Related]
6. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry. Hong PS; Chan KK Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602 [TBL] [Abstract][Full Text] [Related]
7. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Hemminki K Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012 [TBL] [Abstract][Full Text] [Related]
8. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Struck RF; Kirk MC; Witt MH; Laster WR Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393 [TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE; Doeden D; Powers JF; Krivit W Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [TBL] [Abstract][Full Text] [Related]
10. Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide. Bryant BM; Jarman M; Baker MH; Smith IE; Smyth JF Cancer Res; 1980 Dec; 40(12):4734-8. PubMed ID: 7438105 [TBL] [Abstract][Full Text] [Related]
11. Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients. Pallante SL; Fenselau C; Mennel RG; Brundrett RB; Appler M; Rosenshein NB; Colvin M Cancer Res; 1980 Jul; 40(7):2268-72. PubMed ID: 7388793 [TBL] [Abstract][Full Text] [Related]
12. Half-life of oxazaphosphorines in biological fluids. Sladek NE; Powers JF; Grage GM Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904 [TBL] [Abstract][Full Text] [Related]
13. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080 [TBL] [Abstract][Full Text] [Related]
14. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Low JE; Borch RF; Sladek NE Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981 [TBL] [Abstract][Full Text] [Related]
15. Determination of cyclophosphamide metabolites by gas chromatography and thermionic specific detection. Interindividual differences in hepatic biotransformation of cyclophosphamide in man in vitro. Sessink PJ; Vaes WH; van den Broek PH; Noordhoek J; Bos RP J Chromatogr B Biomed Appl; 1995 Nov; 673(2):205-12. PubMed ID: 8611954 [TBL] [Abstract][Full Text] [Related]
16. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration. Struck RF; Alberts DS Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832 [TBL] [Abstract][Full Text] [Related]
17. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Dirven HA; van Ommen B; van Bladeren PJ Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469 [TBL] [Abstract][Full Text] [Related]
18. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Hadidi AH; Coulter CE; Idle JR Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Chan KK; Hong PS; Tutsch K; Trump DL Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837 [TBL] [Abstract][Full Text] [Related]
20. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry. Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]